8th TIL Therapies Summit 2026

TIL Therapies Summit 2026
From discovery to the clinic, this is the leading TIL therapies summit will give you insights to expand patient reach in melanoma, lung and beyond

Expand Patient Access in Solid Tumors with Next‑Generation TIL, Gene Editing, Harmonized Potency & QC Frameworks to Scale Clinical Studies to Commercial Success
With the first TIL Therapy now approved in both the US and Canada, and the field regrouping following a setback in Europe, this is a pivotal time for drug developers looking to address treatment-resistant solid tumors .
Returning for its 8th year, the TIL Therapies Summit remains the go-to forum for this close-knit community, created with the mission to transform end-to-end TIL development and deliver best-in-class therapies to treat solid tumor indications with significant unmet needs.
With more patients being treated than ever, this summit unites a global collective of biopharma, academic thought leaders and clinicians including Curacell , Junecell , Obsidian Therapeutics , AgonOx , as they share their cutting-edge research into engineered TIL, easier manufacturing, QC, Potency, clinical updates, regulatory updates, investment opportunities and more.
I liked networking with colleagues in the field; getting the latest updates about TIL therapy development; getting feedback on our cell therapy pipeline Head of Cell Therapy, Invios